FDA Approves NEURACEQ — Lantheus Biosciences Ltd., a Lantheus company

Lantheus Biosciences has received FDA approval of NEURACEQ® (florbetaben F 18), a molecular imaging agent indicated for the detection of amyloid plaques in the brain. This authorized the introduction of the product in 2014, strengthening Lantheus's portfolio and addressing a critical diagnostic need for patients with cognitive disorders.